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Spice and all things nasty: the challenge of synthetic
cannabinoids
An evolving problem that is difficult to detect and treat
Nicola J Kalk NIHR clinical lecturer 1, Alastair Boyd associate specialist in addiction psychiatry 2,
John Strang professor 1, Emily Finch clinical director of the addictions clinical academic group 2
1National Addictions Centre, King’s College London, London SE5 8BB, UK; 2South London and Maudsley NHS Foundation Trust, London, UK
The Psychoactive Substances Act 2016, which came into force
in May, signals a new approach to drug controls in the UK. For
the first time, the basis for illegality is pharmacological action
rather than chemical structure. The act made it illegal to produce
or supply “spice” or synthetic cannabinoids and to possess them
in a custodial setting.
Synthetic cannabinoids are a group of structurally unrelated
compounds that act at the cannabinoid receptors CB1 and CB2.
Spice is the commonest UK term, but there are more than 500
other street names, including black mamba and annihilation.1
The chemicals are synthesised in a laboratory, dissolved in a
solvent, then sprayed onto plant material, which is smoked or,
less commonly, taken orally or injected. Previous attempts to
ban synthetic cannabinoids failed because compounds with
novel structures could be produced quickly. The clinical
challenge of these substances mirrors the legislative challenge
in that the severity of harms demands a substantial response
while their chemical variety makes monitoring and treatment
challenging.
Scale of the problem
Synthetic cannabinoids are the most commonly used novel
psychoactive substances in Europe and the US.2 3 Their use is
more common in adolescents: 10% of American and 6% of
European teenagers have used synthetic cannabinoids.2 4
Teenagers use them because their previously unregulated status,
availability, and marketing as “herbal” led to the misconception
that they were innocuous.5 In an internet survey 37% of users
reported harmful synthetic cannabinoid use and 15% reported
dependence.6
Up to a third of prisoners in the UK use synthetic cannabinoids,7
possibly as a substitute for cannabis; positive tests for cannabis
have fallen by 59% over the past decade while use of spice has
increased.8 9 Synthetic varieties are often more harmful than
cannabis, and a report from nine English prisons recorded 54
serious incidents in which spice was implicated over three
months in 2015; in 44% of these the prisoner required hospital
admission for toxicity, 19% involved violence, and 9% self
harm.9 These substances have also been associated with
psychosis characterised by aggression and requiring continuing
antipsychotic treatment.5
Greater toxicity can be attributed to three pharmacological
features.10 Firstly, synthetic cannabinoids show a 50-300 times
greater affinity for the CB1 receptor than tetrahydrocannabinol
(THC), so a smaller amount occupies most receptors. Secondly,
they are full agonists at CB1 receptors, whereas
tetrahydrocannabinol is a partial agonist, so stimulate the
receptor more. Thirdly, synthetic cannabinoids are also full
agonists at the CB2 receptor, with downstream effects on other
receptors including the 5HT2A receptor, implicated in
tachycardia and seizures. Other pharmacological effects are less
well described but include modulation of dopamine,
noradrenaline, glutamate, and γ-aminobutyric acid transmission.5
Assessment and treatment
Guidelines produced by NEPTUNE, an expert group of
addictions specialists, toxicologists, and emergency medicine
physicians funded by the Health Foundation to respond to the
challenge of novel psychoactive substances in the UK, provide
an overview of the assessment and treatment of both acute
toxicity and chronic use of synthetic cannabinoids as well as
online educational resources.11Diagnosis of acute toxicity relies
on clinical recognition because synthetic cannabinoids cannot
be detected by routine urine tests.6-12 Clinically, intoxication
resembles cannabis intoxication: conjunctival injection, dry
mouth, cold extremities, tachycardia, and hypertension.13
The NEPTUNE guidelines do not suggest investigations, but
the following may detect reported complications:
electrocardiography to detect arrhythmia and ischaemia; blood
tests for urea and electrolytes, liver enzymes, and glucose; and
blood gases to detect electrolyte disturbance, hepatotoxicity,
renal toxicity, and acidosis.13 Supportive measures, including
intravenous fluids, antiemetics, and benzodiazepines, are the
mainstay of treatment. Second generation antipsychotics are
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recommended for psychotic symptoms because they are 5HT2A
antagonists.11Recommended support for abuse and dependence
includes psychosocial interventions that are effective for all
addictions, including brief intervention, structured psychosocial
support, and signposting to mutual aid, delivered according the
stepped care model prevalent in the UK.11
Synthetic cannabinoids are undoubtedly an increasing problem,
albeit in circumscribed populations. Severe acute toxicity is
common, and dependence is a risk in heavy users. Uncertainty
exists about further spread and route of use, and prevalence in
other vulnerable populations such as psychiatric patients. The
effects of the ban are uncertain: while it may increase users’
perception of harmfulness, there are also harms associated with
illegality, such as criminalisation. The predominant chemical
families of synthetic cannabinoids already in circulation are
unknown, limiting the development of effective urine tests.
Finally, the optimal treatment of toxicity is still unknown.
Although an antidote, rimonabant, exists, it has severe side
effects, and it is unclear how or if it should be used in practice.
Research to identify best practice and best treatments is therefore
a high priority.
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